Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
33
FBIO Quote, Financials, Valuation and Earnings
Last price:
$1.95
Seasonality move
:
-19.35%
Day range:
$1.91 - $2.01
52-week range:
$1.33 - $2.89
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.77x
P/B ratio:
2.62x
Volume:
223.7K
Avg. volume:
239.4K
1-year change:
-2.96%
Market cap:
$58.3M
Revenue:
$57.7M
EPS (TTM):
-$2.23
Analysts' Opinion
-
Consensus RatingFortress Biotech has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $10.00, Fortress Biotech has an estimated upside of 407.61% from its current price of $1.97.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $1.97.
Fair Value
-
According to the consensus of 1 analyst, Fortress Biotech has 407.61% upside to fair value with a price target of $10.00 per share.
FBIO vs. S&P 500
-
Over the past 5 trading days, Fortress Biotech has underperformed the S&P 500 by -1.07% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Fortress Biotech does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Fortress Biotech has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Fortress Biotech reported revenues of $13.1M.
Earnings Growth
-
Fortress Biotech has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Fortress Biotech reported earnings per share of -$0.48.
Enterprise value:
35.4M
EV / Invested capital:
--
Price / LTM sales:
0.77x
EV / EBIT:
--
EV / Revenue:
0.61x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-0.48x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$38.9M
Return On Assets:
-27.09%
Net Income Margin (TTM):
-71.24%
Return On Equity:
--
Return On Invested Capital:
-67.58%
Operating Margin:
-169.85%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $64.2M | $85.1M | $57.8M | $13M | $13.1M | |
| Gross Profit | $35.2M | $62.7M | $38.9M | $7M | $8.3M | |
| Operating Income | -$215.2M | -$116.9M | -$96.9M | -$36.6M | -$22.3M | |
| EBITDA | -$198.3M | -$121.3M | -$88.3M | -$35.8M | -$21M | |
| Diluted EPS | -$16.30 | -$6.16 | -$2.23 | -$1.04 | -$0.48 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $318M | $341.2M | $202.4M | $116.5M | $126.9M | |
| Total Assets | $391M | $407.9M | $263.6M | $164.6M | $178.1M | |
| Current Liabilities | $53.8M | $103.1M | $129.5M | $87.7M | $73.7M | |
| Total Liabilities | $146.8M | $214.4M | $243.7M | $168.6M | $145.6M | |
| Total Equity | $244.2M | $193.6M | $19.8M | -$3.9M | $32.5M | |
| Total Debt | $63.1M | $96.1M | $99.1M | $64.4M | $58.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$175.8M | -$110.4M | -$74.4M | -$25.4M | -$19.6M | |
| Cash From Investing | -$6.6M | $2.9M | -$13.8M | -- | $1.2M | |
| Cash From Financing | $47.5M | $38.4M | $94.9M | $27.9M | $52.1M | |
| Free Cash Flow | -$177.5M | -$110.4M | -$74.4M | -$25.4M | -$19.6M | |
FBIO
Sector
Market Cap
$58.3M
$34.4M
Price % of 52-Week High
68.17%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
-227.33%
-1.01%
1-Year Price Total Return
-2.96%
-37.36%
Beta (5-Year)
1.752
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
-6.54%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.95
200-day SMA
Buy
Level
$1.77
Bollinger Bands (100)
Buy
Level
1.57 - 1.89
Chaikin Money Flow
Buy
Level
183.3K
20-day SMA
Buy
Level
$1.87
Relative Strength Index (RSI14)
Buy
Level
57.30
ADX Line
Sell
Level
22.41
Williams %R
Neutral
Level
-26.6667
50-day SMA
Buy
Level
$1.85
MACD (12, 26)
Buy
Level
0.53
25-day Aroon Oscillator
Sell
Level
-28
On Balance Volume
Neutral
Level
198.8K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-8.8945)
Sell
CA Score
(Annual)
Level (-5.1001)
Buy
Beneish M-Score
(Annual)
Level (-3.8699)
Buy
Momentum Score
Level (6)
Sell
Ohlson Score
Level (6.7283)
Sell
Piotroski F Score
(Annual)
Level (2)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
Stock Forecast FAQ
In the current month, FBIO has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The FBIO average analyst price target in the past 3 months is $10.00.
-
Where Will Fortress Biotech Stock Be In 1 Year?
According to analysts, the consensus estimate is that Fortress Biotech share price will rise to $10.00 per share over the next 12 months.
-
What Do Analysts Say About Fortress Biotech?
Analysts are divided on their view about Fortress Biotech share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Fortress Biotech is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is Fortress Biotech's Price Target?
The price target for Fortress Biotech over the next 1-year time period is forecast to be $10.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is FBIO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Fortress Biotech is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of FBIO?
You can purchase shares of Fortress Biotech via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Fortress Biotech shares.
-
What Is The Fortress Biotech Share Price Today?
Fortress Biotech was last trading at $1.95 per share. This represents the most recent stock quote for Fortress Biotech. Yesterday, Fortress Biotech closed at $1.97 per share.
-
How To Buy Fortress Biotech Stock Online?
In order to purchase Fortress Biotech stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
